PregVac
With an ultimate aim to inform actions that can improve maternal vaccination uptake, the main objectives of PregVac are to quantify maternal vaccination coverage and its sociodemographic correlates in Norway.
About the project
-
Project period: 30.09.2022 - 30.12.2029 (Active)
- Coordinating Institution: Norwegian Institute of Public Health
-
Project Manager:
- Bo Lars Thorvald Terning Hansen, Infection Control and Vaccines
-
Project Participants:
- Hinta Meijerink, Infection Control and Vaccines
- Margrethe Greve-Isdahl, Infection Control and Vaccines
- Jesper Dahl, Infection Control and Vaccines
Summary
Pregnancy and early infancy are periods of relative immune suppression and thus increased vulnerability to infection, which may be associated with higher morbidity. Maternal vaccination, i.e. vaccination during pregnancy, has several potential benefits: protection of the mother from infection that she may be particularly susceptible to, protection of the fetus from harmful effects of maternal infection, and direct protection of the neonate after birth from infection through enhanced transfer of maternal antibodies. In Norway, maternal vaccination is recommended against influenza, COVID-19 and pertussis. With an ultimate aim to inform actions that can improve maternal vaccination uptake, the main objectives of PregVac are to quantify maternal vaccination coverage and its sociodemographic correlates in Norway.